Mineralys Therapeutics' Experimental Drug Significantly Reduces Blood Pressure in Chronic Kidney Disease Patients
Mineralys Therapeutics presented data on May 30, 2026 showing lorundrostat reduced systolic blood pressure by 9.6 mmHg in 192 chronic kidney disease patients and cut urine albumin levels by over half in a subgroup. The once-daily pill, which blocks aldosterone production, is under FDA review with a decision expected by December 2026. AstraZeneca's Baxfendy recently became the first aldosterone-blocking drug approved in the U.S.
Lorundrostat trial results
▪Lorundrostat cut levels of albumin protein in urine by more than half in a subgroup of chronic kidney disease patients who had elevated levels.
▪Mineralys Therapeutics presented new data on lorundrostat at a major European medical conference on May 30, 2026.
▪Lorundrostat showed a placebo-adjusted reduction in systolic blood pressure of 9.6 mmHg at 12 weeks in 192 patients with chronic kidney disease.
▪The lorundrostat trial tested the once-daily pill in 800 patients with uncontrolled or resistant high blood pressure.
▪About 71% of chronic kidney disease patients in the lorundrostat trial were taking three or more blood pressure drugs at baseline.
Chronic kidney disease impact
▪Chronic kidney disease affects more than 37 million Americans.
▪Hypertension is common in people with chronic kidney disease and is linked to a higher risk of heart disease and worsening kidney function.
▪Chronic kidney disease is closely tied to high blood pressure.
Hypertension global burden
▪Hypertension affects about 1.4 billion people worldwide.
▪Hypertension is a major cause of premature death worldwide.
Competitive landscape
▪Baxfendy is the first drug in a class that works by blocking aldosterone to win U.S. approval.
▪AstraZeneca's hypertension pill Baxfendy was recently approved in the United States.
▪Lorundrostat works by blocking aldosterone production.
▪Lorundrostat is under review by the U.S. FDA with a decision expected by December 2026.
Story comments
Loading comments…